NETO2

Summary

NETO2 (neuropilin and tolloid like 2, HGNC:14644) is a protein-coding gene on chromosome 16q12.1, encoding Neuropilin and tolloid-like protein 2 (Q8NC67). Accessory subunit of neuronal kainate-sensitive glutamate receptors, GRIK2 and GRIK3.

This gene encodes a predicted transmembrane protein containing two extracellular CUB domains followed by a low-density lipoprotein class A (LDLa) domain. A similar gene in rats encodes a protein that modulates glutamate signaling in the brain by regulating kainate receptor function. Expression of this gene may be a biomarker for proliferating infantile hemangiomas. A pseudogene of this gene is located on the long arm of chromosome 8. Alternatively spliced transcript variants encoding multiple isoforms have been observed for this gene.

Source: NCBI Gene 81831 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 82 total
• MANE Select transcript: NM_018092

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:14644
Approved symbol	NETO2
Name	neuropilin and tolloid like 2
Location	16q12.1
Locus type	gene with protein product
Status	Approved
Aliases	FLJ10430, NEOT2
Ensembl gene	ENSG00000171208
Ensembl biotype	protein_coding
OMIM	607974
Entrez	81831

Gene structure

Transcript identifiers

Ensembl transcripts: 12 — 12 protein_coding

ENST00000303155, ENST00000562435, ENST00000562559, ENST00000563078, ENST00000564667, ENST00000878302, ENST00000878303, ENST00000878304, ENST00000935728, ENST00000935729, ENST00000935730, ENST00000962554

RefSeq mRNA: 2 — MANE Select: NM_018092 NM_001201477, NM_018092

CCDS: CCDS10727, CCDS58460

Canonical transcript exons

ENST00000562435 — 9 exons

Exon	Start	End
ENSE00001131266	47122657	47122784
ENSE00001131270	47128325	47128573
ENSE00001131278	47129224	47129364
ENSE00001165245	47109483	47109711
ENSE00001245750	47122868	47122912
ENSE00001319075	47131969	47132025
ENSE00001388767	47143579	47143945
ENSE00001696301	47086226	47086339
ENSE00002628768	47077703	47083801

Expression profiles

Bgee: expression breadth ubiquitous, 228 present calls, max score 97.72.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 15.0825 / max 255.9362, expressed in 1693 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
157233	7.3756	1460
157234	6.5569	1582
157235	1.1500	792

Top tissues by expression

277 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
secondary oocyte	CL:0000655	97.72	gold quality
cortical plate	UBERON:0005343	96.87	gold quality
ganglionic eminence	UBERON:0004023	95.61	gold quality
oocyte	CL:0000023	94.71	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	92.60	gold quality
pigmented layer of retina	UBERON:0001782	92.59	gold quality
retina	UBERON:0000966	92.57	gold quality
embryo	UBERON:0000922	91.34	gold quality
adrenal tissue	UBERON:0018303	90.93	gold quality
ventricular zone	UBERON:0003053	89.17	gold quality
Brodmann (1909) area 46	UBERON:0006483	88.95	gold quality
middle temporal gyrus	UBERON:0002771	87.36	gold quality
nucleus accumbens	UBERON:0001882	86.19	gold quality
orbitofrontal cortex	UBERON:0004167	85.96	gold quality
prefrontal cortex	UBERON:0000451	85.69	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	85.58	gold quality
Brodmann (1909) area 23	UBERON:0013554	85.28	gold quality
caudate nucleus	UBERON:0001873	85.14	gold quality
stromal cell of endometrium	CL:0002255	84.89	gold quality
superior frontal gyrus	UBERON:0002661	84.55	gold quality
mucosa of transverse colon	UBERON:0004991	84.55	gold quality
putamen	UBERON:0001874	84.32	gold quality
frontal cortex	UBERON:0001870	83.39	gold quality
frontal lobe	UBERON:0016525	83.39	gold quality
monocyte	CL:0000576	83.31	gold quality
visceral pleura	UBERON:0002401	83.08	gold quality
neocortex	UBERON:0001950	83.07	gold quality
mononuclear cell	CL:0000842	83.00	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	82.81	gold quality
spleen	UBERON:0002106	82.50	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	4.79
E-CURD-112	no	2.00

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): NME1

miRNA regulators (miRDB)

113 targeting NETO2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3646	100.00	73.56	5283
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-511-3P	99.99	68.85	1467
HSA-MIR-150-5P	99.99	66.69	1976
HSA-MIR-4789-3P	99.99	70.75	2484
HSA-MIR-186-5P	99.99	70.83	3707
HSA-MIR-12136	99.98	72.81	5713
HSA-MIR-302C-5P	99.97	72.56	3642
HSA-MIR-607	99.97	73.62	5593
HSA-MIR-3148	99.97	75.06	6478
HSA-MIR-570-3P	99.96	72.41	4910
HSA-MIR-548AT-5P	99.96	70.83	2666
HSA-MIR-493-5P	99.96	72.47	2382
HSA-MIR-128-3P	99.95	71.17	2484
HSA-MIR-216A-3P	99.95	71.19	2505
HSA-LET-7C-3P	99.95	73.42	2862
HSA-MIR-144-3P	99.94	73.98	2698
HSA-MIR-651-3P	99.94	73.48	5177
HSA-MIR-101-3P	99.94	75.03	2230
HSA-MIR-1-3P	99.93	72.35	1914
HSA-MIR-206	99.93	72.50	1893
HSA-MIR-335-3P	99.93	73.36	4958
HSA-MIR-338-5P	99.92	72.34	2951
HSA-MIR-6508-5P	99.92	70.67	2465
HSA-MIR-7-1-3P	99.91	71.53	4384
HSA-MIR-7-2-3P	99.91	71.40	4394
HSA-MIR-613	99.91	71.50	1710
HSA-MIR-3671	99.90	73.04	3897
HSA-MIR-106A-5P	99.90	73.94	2683

Literature-anchored findings (GeneRIF, showing 13)

• Determination of the neuropilin and tolloid-like protein 2 signal peptide cleavage site by N-terminal sequencing. (PMID:15340161)
• Rat neto2 plays a role in glutamate signaling in the brain by modulating the function of kainate receptors. (PMID:19217376)
• Results suggested that the extracellular N-terminal region including the two CUB domains was largely responsible for the distinct regulatory effects of Neto1 and Neto2 on the desensitization properties of GluK1 homomeric receptors (PMID:26277340)
• NETO2 upregulation could serve as a potential biomarker for the prediction of advanced tumor progression and unfavorable prognosis in patients with colorectal carcinoma. (PMID:26699544)
• NETO2 may be involved in colorectal cancer progression, but is not directly associated with epithelial-mesenchymal transition (PMID:29297384)
• upregulation of NETO2 gene is first stipulated by the isoform 1 (NM_018092.4), and the probable mechanism of its activation is associated with the increased expression of SAP30 transcription factor. (PMID:29989576)
• NETO2 promotes invasion and metastasis of gastric cancer cells and represents a novel prognostic indicator as well as a potential therapeutic target in gastric cancer. (PMID:30770791)
• NETO2 expression is up-regulated in Nasopharyngeal carcinoma (NPC) clinical specimens and cell lines. NETO2 down-regulation reduces proliferation, migration and invasion in irradiated NPC cell lines. (PMID:30975469)
• Neuropilin and tolloid-like 2 regulates the progression of osteosarcoma. (PMID:33157203)
• NETO2 promotes esophageal cancer progression by inducing proliferation and metastasis via PI3K/AKT and ERK pathway. (PMID:33390848)
• Kainate receptor modulation by NETO2. (PMID:34552241)
• Glioma-derived LRIG3 interacts with NETO2 in tumor-associated macrophages to modulate microenvironment and suppress tumor growth. (PMID:36639372)
• NETO2 promotes melanoma progression via activation of the Ca[2+]/CaMKII signaling pathway. (PMID:36738427)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	neto2b	ENSDARG00000063293
danio_rerio	NETO2	ENSDARG00000112100
mus_musculus	Neto2	ENSMUSG00000036902
rattus_norvegicus	Neto2	ENSRNOG00000016245

Paralogs (35): NRXN3 (ENSG00000021645), TLL1 (ENSG00000038295), CP (ENSG00000047457), DCBLD2 (ENSG00000057019), HEPH (ENSG00000089472), TLL2 (ENSG00000095587), NRP1 (ENSG00000099250), PCOLCE (ENSG00000106333), CNTNAP3 (ENSG00000106714), CUBN (ENSG00000107611), CNTNAP1 (ENSG00000108797), NRXN2 (ENSG00000110076), MEP1A (ENSG00000112818), NRP2 (ENSG00000118257), CUZD1 (ENSG00000138161), MFGE8 (ENSG00000140545), MEP1B (ENSG00000141434), PDGFC (ENSG00000145431), CNTNAP4 (ENSG00000152910), CNTNAP3B (ENSG00000154529), CNTNAP5 (ENSG00000155052), CDCP2 (ENSG00000157211), PCOLCE2 (ENSG00000163710), EDIL3 (ENSG00000164176), NETO1 (ENSG00000166342), BMP1 (ENSG00000168487), PDGFD (ENSG00000170962), CNTNAP2 (ENSG00000174469), NRXN1 (ENSG00000179915), HEPHL1 (ENSG00000181333), F8 (ENSG00000185010), ASTL (ENSG00000188886), F5 (ENSG00000198734), MFRP (ENSG00000235718), CNTNAP3C (ENSG00000283378)

Protein

Protein identifiers

Neuropilin and tolloid-like protein 2 — Q8NC67 (reviewed: Q8NC67)

Alternative names: Brain-specific transmembrane protein containing 2 CUB and 1 LDL-receptor class A domains protein 2

All UniProt accessions (4): H3BM37, H3BSR0, H3BTE1, Q8NC67

UniProt curated annotations — full annotation on UniProt →

Function. Accessory subunit of neuronal kainate-sensitive glutamate receptors, GRIK2 and GRIK3. Increases kainate-receptor channel activity, slowing the decay kinetics of the receptors, without affecting their expression at the cell surface, and increasing the open probability of the receptor channels. Modulates the agonist sensitivity of kainate receptors. Slows the decay of kainate receptor-mediated excitatory postsynaptic currents (EPSCs), thus directly influencing synaptic transmission.

Subunit / interactions. Interacts with GRIK2 and GRIK3, but neither with AMPA-nor with NMDA-sensitive glutamate receptors.

Subcellular location. Membrane.

Post-translational modifications. N-glycosylated.

Isoforms (3)

UniProt ID	Names	Canonical?
Q8NC67-1	1	yes
Q8NC67-2	2
Q8NC67-3	3

RefSeq proteins (2): NP_001188406, NP_060562* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000859	CUB_dom	Domain
IPR002172	LDrepeatLR_classA_rpt	Repeat
IPR023415	LDLR_class-A_CS	Conserved_site
IPR035914	Sperma_CUB_dom_sf	Homologous_superfamily
IPR036055	LDL_receptor-like_sf	Homologous_superfamily

Pfam: PF00057, PF00431

UniProt features (26 total): disulfide bond 7, sequence conflict 5, splice variant 3, domain 3, topological domain 2, signal peptide 1, chain 1, sequence variant 1, transmembrane region 1, modified residue 1, glycosylation site 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q8NC67-F1	72.14	0.45

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (1): 409

Disulfide bonds (7): 45–72, 100–122, 177–207, 234–256, 297–309, 304–322, 316–331

Glycosylation sites (1): 311

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 211 (showing top): ELVIDGE_HYPOXIA_DN, RODRIGUES_THYROID_CARCINOMA_POORLY_DIFFERENTIATED_UP, TGCACTT_MIR519C_MIR519B_MIR519A, GAUSSMANN_MLL_AF4_FUSION_TARGETS_C_UP, LEE_LIVER_CANCER_CIPROFIBRATE_DN, GOBP_PROTEIN_LOCALIZATION_TO_CELL_PERIPHERY, WEI_MYCN_TARGETS_WITH_E_BOX, TONKS_TARGETS_OF_RUNX1_RUNX1T1_FUSION_ERYTHROCYTE_UP, CADWELL_ATG16L1_TARGETS_DN, ONKEN_UVEAL_MELANOMA_UP, RUTELLA_RESPONSE_TO_CSF2RB_AND_IL4_UP, GOBP_REGULATION_OF_CELLULAR_LOCALIZATION, BILD_E2F3_ONCOGENIC_SIGNATURE, RUTELLA_RESPONSE_TO_HGF_VS_CSF2RB_AND_IL4_DN, LIAO_METASTASIS

GO Biological Process (2): regulation of neurotransmitter receptor localization to postsynaptic specialization membrane (GO:0098696), neurotransmitter receptor localization to postsynaptic specialization membrane (GO:0099645)

GO Molecular Function (2): ionotropic glutamate receptor binding (GO:0035255), protein binding (GO:0005515)

GO Cellular Component (5): postsynaptic density (GO:0014069), postsynaptic density membrane (GO:0098839), glutamatergic synapse (GO:0098978), membrane (GO:0016020), synapse (GO:0045202)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
regulation of biological quality	1
neurotransmitter receptor localization to postsynaptic specialization membrane	1
regulation of protein localization to synapse	1
regulation of receptor localization to synapse	1
regulation of protein localization to cell periphery	1
regulation of protein localization to membrane	1
protein-containing complex localization	1
receptor localization to synapse	1
regulation of postsynaptic membrane neurotransmitter receptor levels	1
protein localization to postsynaptic specialization membrane	1
glutamate receptor binding	1
binding	1
asymmetric synapse	1
postsynaptic specialization	1
postsynaptic density	1
postsynaptic membrane	1
postsynaptic specialization membrane	1
synapse	1
cellular anatomical structure	1
cell junction	1

Protein interactions and networks

STRING

612 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
NETO2	GRIK2	Q13002	869
NETO2	KARS1	Q15046	811
NETO2	SLC12A5	Q9H2X9	808
NETO2	GRIK1	P39086	642
NETO2	GRIK4	Q16099	577
NETO2	GRIK5	Q16478	570
NETO2	C1R	P00736	570
NETO2	C1S	P09871	540
NETO2	EPB41L1	Q9H4G0	536
NETO2	ARHGEF7	Q14155	529
NETO2	CACNG2	Q9Y698	507
NETO2	CNIH2	Q6PI25	507
NETO2	CNIH4	Q9P003	505
NETO2	CNIH1	O95406	490
NETO2	GPHN	Q9NQX3	471

IntAct

54 interactions, top by confidence:

A	B	Type	Score
HLA-DRA	HLA-DRB1	psi-mi:“MI:0914”(association)	0.880
HLA-C	HLA-A	psi-mi:“MI:0914”(association)	0.670
SLC39A5	FAM171A2	psi-mi:“MI:0914”(association)	0.640
TMEM30B	KLRG2	psi-mi:“MI:0914”(association)	0.530
ZNRF4	UPK3BL1	psi-mi:“MI:0914”(association)	0.530
ADAM33	LRP5	psi-mi:“MI:0914”(association)	0.530
IL9R	RETSAT	psi-mi:“MI:0914”(association)	0.530
IL13RA2	METTL15	psi-mi:“MI:0914”(association)	0.530
TMED6	SMPD2	psi-mi:“MI:0914”(association)	0.530
NETO2	TIA1	psi-mi:“MI:0914”(association)	0.350
HTR3C	TMEM223	psi-mi:“MI:0914”(association)	0.350
CLEC2D	TMEM120B	psi-mi:“MI:0914”(association)	0.350
BTNL8	TMEM131L	psi-mi:“MI:0914”(association)	0.350
TMPRSS3	UPK3BL1	psi-mi:“MI:0914”(association)	0.350
TMED6	UPK3BL1	psi-mi:“MI:0914”(association)	0.350
ASIC4	UPK3BL1	psi-mi:“MI:0914”(association)	0.350
PTCH1	PLXNB2	psi-mi:“MI:0914”(association)	0.350
HTR3A	GPAA1	psi-mi:“MI:0914”(association)	0.350
PON2	ENTPD6	psi-mi:“MI:0914”(association)	0.350
NS3	C15orf61	psi-mi:“MI:0914”(association)	0.350
	SHTN1	psi-mi:“MI:0914”(association)	0.350
	TMEM223	psi-mi:“MI:0914”(association)	0.350
	SURF4	psi-mi:“MI:0914”(association)	0.350
CANX	HLA-A	psi-mi:“MI:0914”(association)	0.350
CHRNA4	TMEM223	psi-mi:“MI:0914”(association)	0.350
LDLRAD1	GXYLT2	psi-mi:“MI:0914”(association)	0.350
CLEC12B	GXYLT2	psi-mi:“MI:0914”(association)	0.350

BioGRID (105): NETO2 (Affinity Capture-MS), NETO2 (Affinity Capture-MS), NETO2 (Affinity Capture-MS), NETO2 (Affinity Capture-MS), NETO2 (Affinity Capture-MS), NETO2 (Affinity Capture-MS), NETO2 (Affinity Capture-MS), NETO2 (Affinity Capture-MS), NETO2 (Affinity Capture-MS), NETO2 (Affinity Capture-MS), NETO2 (Affinity Capture-MS), NETO2 (Proximity Label-MS), KRT17 (Affinity Capture-MS), TIA1 (Affinity Capture-MS), AIMP2 (Affinity Capture-MS)

ESM2 similar proteins: A1XQX1, A1XQX3, A1XQY0, A8WGA3, C6K2K4, D0PRN2, D0PRN4, D4A1J9, E9PUN2, O13097, O42596, O73612, O73874, P0DI97, P52795, P52796, P58400, P58401, P98172, Q01974, Q0PMD2, Q17QD6, Q28142, Q28143, Q460M5, Q63373, Q63376, Q6NW40, Q6PCX7, Q6PFE7, Q7TQ33, Q80TG9, Q8BNJ6, Q8BXA0, Q8C985, Q8IYR6, Q8NC67, Q91590, Q96B86, Q96NI6

Diamond homologs: A0A0C5PRQ1, A0FKN6, A0JNA2, A8Q2D1, C6K2K4, C9D7R3, D2KBH9, D5FM34, D5FM37, D5FM38, K7Z9Q9, O16977, O17264, O35276, O35375, O43897, O57382, O57460, O60462, O60494, O70244, P07584, P0DM61, P0DM62, P13497, P28825, P28826, P31579, P31580, P31581, P42674, P55112, P55113, P55114, P55115, P84748, P91828, P98060, P98061, P98068

SIGNOR signaling

1 interactions.

A	Effect	B	Mechanism
NME1	“down-regulates quantity by repression”	NETO2	“transcriptional regulation”

Disease & clinical

Clinical variants and AI predictions

ClinVar

82 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	71
Likely benign	0
Benign	1

Top pathogenic / likely-pathogenic (0)

SpliceAI

1805 predictions. Top by Δscore:

Variant	Effect	Δscore
16:47083797:CTTTT:C	acceptor_gain	1.0000
16:47083802:C:CC	acceptor_gain	1.0000
16:47109481:A:AC	donor_gain	1.0000
16:47109481:ACGCT:A	donor_gain	1.0000
16:47109482:C:CC	donor_gain	1.0000
16:47109482:CG:C	donor_gain	1.0000
16:47109482:CGCT:C	donor_gain	1.0000
16:47109482:CGCTC:C	donor_gain	1.0000
16:47122661:G:C	donor_gain	1.0000
16:47128571:CAG:C	acceptor_gain	1.0000
16:47128574:C:CC	acceptor_gain	1.0000
16:47129219:AATAC:A	donor_loss	1.0000
16:47129220:ATACC:A	donor_loss	1.0000
16:47129221:TACC:T	donor_loss	1.0000
16:47129222:A:T	donor_loss	1.0000
16:47129226:T:A	donor_gain	1.0000
16:47129244:T:A	donor_gain	1.0000
16:47129361:CCAT:C	acceptor_gain	1.0000
16:47129362:CAT:C	acceptor_gain	1.0000
16:47129362:CATC:C	acceptor_gain	1.0000
16:47129365:C:CC	acceptor_gain	1.0000
16:47129366:T:C	acceptor_gain	1.0000
16:47129366:T:TC	acceptor_gain	1.0000
16:47132021:CAACA:C	acceptor_gain	1.0000
16:47132024:CA:C	acceptor_gain	1.0000
16:47132026:C:CC	acceptor_gain	1.0000
16:47143573:CCTTA:C	donor_loss	1.0000
16:47143574:CTTA:C	donor_loss	1.0000
16:47143575:TTAC:T	donor_loss	1.0000
16:47143576:TAC:T	donor_loss	1.0000

AlphaMissense

3486 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
16:47109644:A:T	V241D	1.000
16:47109650:A:T	V239D	1.000
16:47128483:C:G	R108P	1.000
16:47128507:C:G	C100S	1.000
16:47128508:A:G	C100R	1.000
16:47128508:A:T	C100S	1.000
16:47086297:C:G	C309S	0.999
16:47086298:A:T	C309S	0.999
16:47109541:C:A	W275C	0.999
16:47109541:C:G	W275C	0.999
16:47109548:C:G	R273P	0.999
16:47109598:G:C	C256W	0.999
16:47109599:C:G	C256S	0.999
16:47109599:C:T	C256Y	0.999
16:47109600:A:G	C256R	0.999
16:47109600:A:T	C256S	0.999
16:47109648:C:G	A240P	0.999
16:47109665:C:G	C234S	0.999
16:47109666:A:G	C234R	0.999
16:47109666:A:T	C234S	0.999
16:47109698:A:G	F223S	0.999
16:47122684:C:A	W209C	0.999
16:47122684:C:G	W209C	0.999
16:47122686:A:G	W209R	0.999
16:47122686:A:T	W209R	0.999
16:47122690:G:C	C207W	0.999
16:47122691:C:G	C207S	0.999
16:47122692:A:G	C207R	0.999
16:47122692:A:T	C207S	0.999
16:47128340:A:C	Y156D	0.999

dbSNP variants (sampled 300 via entrez): RS1000016477 (16:47140828 G>C), RS1000028197 (16:47133719 A>G), RS1000051598 (16:47103866 GA>G,GAA), RS1000127005 (16:47111164 A>G,T), RS1000129428 (16:47141472 A>C), RS1000158179 (16:47089376 C>A), RS1000212095 (16:47097083 TA>T), RS1000241335 (16:47113674 C>T), RS1000332820 (16:47120093 A>T), RS1000440309 (16:47090516 G>A), RS1000469949 (16:47120608 T>C), RS1000553837 (16:47108618 T>A), RS1000700888 (16:47121267 T>C), RS1000781737 (16:47114977 A>G), RS1000806639 (16:47121822 T>C)

Disease associations

OMIM: gene MIM:607974 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): prostate cancer (MONDO:0008315)

Orphanet (1): Familial prostate cancer (Orphanet:1331)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D011471	Prostatic Neoplasms	C04.588.945.440.770; C12.100.500.260.750; C12.100.500.565.625; C12.200.294.260.750; C12.200.294.565.625; C12.200.758.409.750; C12.900.619.750

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

53 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects expression, decreases expression, increases methylation	6
bisphenol A	increases expression, affects cotreatment, decreases expression	3
7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide	decreases expression, increases expression	3
sodium arsenite	decreases expression, affects cotreatment, increases abundance	2
belinostat	affects cotreatment, decreases expression	2
Benzo(a)pyrene	affects methylation, increases expression	2
Tretinoin	decreases expression	2
cobaltous chloride	decreases expression	1
manganese chloride	increases abundance, affects cotreatment, decreases expression	1
ochratoxin A	increases acetylation	1
potassium chromate(VI)	decreases expression	1
perfluorooctane sulfonic acid	decreases expression	1
CGP 52608	affects binding, increases reaction	1
2-palmitoylglycerol	increases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression	1
erucylphospho-N,N,N-trimethylpropylammonium	decreases expression	1
abrine	decreases expression	1
dorsomorphin	decreases expression, affects cotreatment	1
incobotulinumtoxinA	decreases expression	1
Bortezomib	decreases expression	1
Temozolomide	decreases expression	1
Sunitinib	decreases expression	1
Arsenic Trioxide	decreases expression	1
Acetaminophen	increases expression	1
Arsenic	decreases expression, increases abundance, affects cotreatment	1
Atrazine	decreases expression	1
Carbamazepine	affects expression	1
Cocaine	increases expression	1
Coumestrol	increases expression	1
Cyclophosphamide	increases expression	1

Cellosaurus cell lines

1 cell lines: 1 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_F1M7	HyCyte A-549 KO-hNETO2	Cancer cell line	Male

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00029224	PHASE4	COMPLETED	Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
NCT00035997	PHASE4	COMPLETED	Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis
NCT00063609	PHASE4	COMPLETED	The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy
NCT00103623	PHASE4	SUSPENDED	The Plenaxis® Experience Study
NCT00106392	PHASE4	COMPLETED	A Safety and Efficacy Study of Prograf in the Prevention of Erectile Dysfunction After Radical Prostatectomy
NCT00185029	PHASE4	UNKNOWN	MR-Lymphography and Lymph Node Staging in Prostate Cancer
NCT00199485	PHASE4	COMPLETED	Angelica Sinensis for the Treatment of Hot Flashes in Men Undergoing LHRH Therapy for Prostate Cancer
NCT00219219	PHASE4	COMPLETED	Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases
NCT00219271	PHASE4	COMPLETED	Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer
NCT00237146	PHASE4	COMPLETED	Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy
NCT00242554	PHASE4	COMPLETED	Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases
NCT00280098	PHASE4	COMPLETED	Docetaxel in the Treatment of Hormone Refractory Prostate Cancer
NCT00293696	PHASE4	COMPLETED	Casodex/Zoladex Biomarkers in Localised Prostate Cancer
NCT00334139	PHASE4	COMPLETED	Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer
NCT00375765	PHASE4	COMPLETED	Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer
NCT00391690	PHASE4	COMPLETED	Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer
NCT00422708	PHASE4	COMPLETED	Local Anesthesia for Prostate Biopsy
NCT00526331	PHASE4	COMPLETED	Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy
NCT00590213	PHASE4	COMPLETED	Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX
NCT00629330	PHASE4	TERMINATED	Dissemination of Prostate Cancer Screening to PCP’s in African American Communities
NCT00771966	PHASE4	COMPLETED	Radical Prostatectomy and Perioperative Fluid Therapy
NCT00805701	PHASE4	COMPLETED	Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation
NCT00859027	PHASE4	COMPLETED	Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer
NCT00906269	PHASE4	UNKNOWN	Can Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer
NCT00953277	PHASE4	COMPLETED	Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer
NCT00982800	PHASE4	COMPLETED	Does Postoperative Gabapentin Reduce Pain, Opioid Consumption and Anxiety and Have a Positive Effect on Health Related Quality of Life After Radical Prostatectomy?
NCT01083199	PHASE4	COMPLETED	Global Performance Evaluation of the AMS CONTINUUM™ Device
NCT01136226	PHASE4	COMPLETED	Evaluate Recovery of Testosterone for Patients Using Eligard
NCT01161563	PHASE4	COMPLETED	Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration
NCT01230905	PHASE4	COMPLETED	Study to Monitor the Effects of Androgen Suppression Treatment on the Heart
NCT01296672	PHASE4	COMPLETED	3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer
NCT01365143	PHASE4	TERMINATED	Prospective Randomized Trial Comparing Robotic Versus Open Radical Prostatectomy
NCT01379742	PHASE4	UNKNOWN	Comparison of Between ThinSeed™ and OncoSeed™ for Permanent Prostate Brachytherapy
NCT01486563	PHASE4	COMPLETED	Hydroxyethyl Starch and Renal Function After Radical Prostatectomy
NCT01511874	PHASE4	COMPLETED	Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer
NCT01512472	PHASE4	TERMINATED	Firmagon (Degarelix) Intermittent Therapy
NCT01547416	PHASE4	COMPLETED	The Effect of Combined General/Epidural Anesthesia Versus General Anesthesia on Diaphragmatic Function
NCT01571544	PHASE4	COMPLETED	The Use of Thermal Suits as Preventing Hypothermia During Surgery
NCT01581749	PHASE4	UNKNOWN	Evaluation of Truebeam for Low-Intermediate Risk Prostate Cancer
NCT01649635	PHASE4	COMPLETED	Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer